Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2025), eClinicalMedicine, 81, 103080 - 103080
Multi-antigen serology and a diagnostic algorithm for the detection of arbovirus infections as novel tools for arbovirus preparedness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Kasbergen LMR. et al, (2025), The Lancet Infectious Diseases
Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study
Sigfrid L. et al, (2025), The Lancet Infectious Diseases
Factors that influence recruitment to COVID-19 vaccine trials: a qualitative evidence synthesis
Biesty L. et al, (2024), Trials, 25
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
Autochthonous Human Babesia divergens Infection, England
Zabala GA. et al, (2024), Emerging Infectious Diseases, 30
Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials
Chan XHS. et al, (2024)
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
Faust SN. et al, (2024), The Lancet Child & Adolescent Health, 8, 190 - 200
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2023), The Lancet Diabetes & Endocrinology, 11, 905 - 914
Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis
Meskell P. et al, (2023), Cochrane Database of Systematic Reviews, 2023
Raising awareness of antimicrobial resistance: development of an ‘antibiotic footprint calculator’
Prapharsavat R. et al, (2023), Journal of Antimicrobial Chemotherapy, 78, 1317 - 1321
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2023), The Lancet, 401, 1499 - 1507
Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years
Imdad A. et al, (2023), Cochrane Database of Systematic Reviews, 2023
Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies
Chan XHS. et al, (2023), British Journal of Clinical Pharmacology, 89, 1176 - 1186
Chest radiograph classification and severity of suspected COVID-19 by different radiologist groups and attending clinicians: multi-reader, multi-case study
Nair A. et al, (2022), European Radiology, 33, 2096 - 2104
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Abani O. et al, (2022), The Lancet, 400, 359 - 368
Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality.
Chan XHS. et al, (2022), The Journal of hospital infection, 124, 37 - 46
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2022), The Lancet, 399, 665 - 676
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2022), The Lancet, 399, 143 - 151
Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis
Meskell P. et al, (2022), The Cochrane database of systematic reviews, 2022